Table 1.
Clinical and demographic characteristics at baseline
| Total | |||
|---|---|---|---|
| Age, years, mean (SD) | 282 | 73.3 | (8.8) |
| Female, n (%) | 282 | 153 | (54.3) |
| Education, years, mean (SD) | 282 | 11.7 | (3.6) |
| Drugs in regular use, mean (SD) | 280 | 3.1 | (2.6) |
| Antihypertensives, number of users (%) | 280 | 137 | (48.9) |
| Statins, number of users (%) | 280 | 85 | (14.7) |
| Antidiabetic agents (number of users, %) | 280 | 20 | (7.1) |
| Antithrombotic agents (number of users, %) | 280 | 131 | (46.8) |
| Platelet inhibitors (number of users, %) | 280 | 114 | (40.4) |
| Anticoagulants (number of users, %) | 280 | 21 | (7.5) |
| ApoE ε4 carrier, n (%) | 252 | 154 | (61.1) |
| MMSE (0–30), mean (SD) | 280 | 23.7 | (4.4) |
| CDR sum of boxes (0–18), mean (SD) | 282 | 4.2 | (2.8) |
| Vascular risk factors (VRFs) | |||
| Hypertension, n (%) | 282 | 234 | (83.0) |
| Hypercholesterolemia, n (%) | 282 | 149 | (52.8) |
| Diabetes mellitus, n (%) | 282 | 26 | (9.2) |
| Overweight (BMI > 25), n (%) | 256 | 106 | (41.4) |
| Smoking (current), n (%) | 275 | 26 | (9.5) |
| Framingham Stroke Risk Profileb (0–1), women, mean (SD) | 113 | 0.21 | (0.14) |
| Framingham Stroke Risk Profileb (0–1), men, mean (SD) | 92 | 0.26 | (0.16) |
| Vascular diseases | |||
| Atrial fibrillation, n (%) | 282 | 28 | (9.9) |
| History of cerebrovascular event (stroke or TIA), n (%) | 282 | 43 | (15.2) |
| History of heart disease, n (%) | 282 | 46 | (16.3) |
| Left ventricular hypertrophy in ECGa, n (%) | 211 | 8 | (3.8) |
| History of peripheral vascular disease, n (%) | 273 | 7 | (2.6) |
| Estimated GFR < 60 ml/min/1.73m2, n (%) | 273 | 47 | (17.2) |
| MRI findings | |||
| Medial temporal lobe atrophy (mean of both sides), mean (SD) | 203 | 1.9 | (0.9) |
| Cortical infarcts, n (%) | 206 | 9 | (4.4) |
| Lacunar infarcts, n (%) | 206 | 33 | (16.0) |
| White matter hyperintensities | |||
| Fazekas 0 or 1, n (%) | 205 | 84 | (40.9) |
| Fazekas 2, n (%) | 205 | 53 | (25.9) |
| Fazekas 3, n (%) | 205 | 68 | (33.2) |
| Cerebrovascular disease: cortical infarcts, lacunes or Fazekas ≥2, n | 206 | 128 | (62.1) |
| Cerebrovascular disease: cortical infarcts, lacunes or Fazekas 3, n | 206 | 88 | (42.7) |
aFramingham criteria
bTen year probability of stroke